A new chemical reaction called 'metallacycle-mediated cross-coupling' created by chemists at Dartmouth College, United States, has the potential to facilitate the search for pharmaceutical drugs.
Organic synthesis is a scientific discipline central to the drug discovery process that is focused on building new carbon-based molecules that can affect biology, for example, targeting and destroying cancer cells.
Study Underlines Urgent Need to Increase Number of Agents Used in Alzheimer's Drug Development
There is an urgent need to increase the number of new agents used in developing new Alzheimer's drugs.
Advertisement
In the study, the Dartmouth College authors describe a new chemical reaction that converts simple starting materials into architecturally complex molecules called "decalins" in a single step. Decalins are carbon-based compounds containing two hexagon rings.
Co-author Glenn Micalizio said that the findings are noteworthy not only because this chemical reaction simplifies the laboratory preparation of such species, but also because our study reveals a unique mode of reactivity associated with metal-carbon bonds that are embedded in complex carbon-based structures.
![Researcher Pinpoints New Target for Leukemia Drug Development]( "Researcher Pinpoints New Target for Leukemia Drug Development")
There are many potentially effective treatments for acute myeloid leukemia (AML) but they work only in 20 to 40 percent of cases.
Micalizio noted that general species of the type studied here have previously been thought to be fleeting intermediates whose reactivity was difficult to control, adding that an important part of this paper demonstrates our ability to reveal new reactivity patterns of these species, prompting them to engage in highly selective chemical transformations.
This latest finding provides a concise and direct synthesis pathway that, due to the structure of the products delivered, will likely be quite valuable for the discovery and development of therapeutic agents, added Micalizio.
The findings appear in the Journal of the American Chemical Society.
Source: Medindia
Researcher Pinpoints New Target for Leukemia Drug Development
There are many potentially effective treatments for acute myeloid leukemia (AML) but they work only in 20 to 40 percent of cases.
Advertisement
Micalizio noted that general species of the type studied here have previously been thought to be fleeting intermediates whose reactivity was difficult to control, adding that an important part of this paper demonstrates our ability to reveal new reactivity patterns of these species, prompting them to engage in highly selective chemical transformations.
This latest finding provides a concise and direct synthesis pathway that, due to the structure of the products delivered, will likely be quite valuable for the discovery and development of therapeutic agents, added Micalizio.
The findings appear in the Journal of the American Chemical Society.
Source: Medindia
Epilepsy Treatment in Mice Gives Hope for Drug Development
Temporal lobe epilepsy is the most common form of epilepsy. It is characterized by recurrent seizures throughout life and often behavioral abnormalities, with devastating impacts on patients and their families.
Advertisement
 New Target for Cancer Drug Development IdentifiedUNC researchers have uncovered a prime suspect for new cancer drug development thanks to a mysterious form of cell death, coded in proteins and enzymes. | Advertisement
|
Advertisement
Recommended Reading
Latest Drug News
Safety and effectiveness of commonly used painkillers (analgesics) for short-term relief of low back pain remain uncertain.
India's First Urinary Incontinence Drug Fesobig may offer Affordable treatment for Overactive Bladder (OAB), a widely prevalent problem among Indian men and women.
Oral anticoagulant drugs, particularly Rivaroxaban presented superior efficacy and safety than warfarin in atrial fibrillation patients with chronic kidney disease.
Patients with hepatitis D virus-related chronic advanced liver disease are treated with an antiviral therapy.
Among people with COVID-19, Paxlovid drug was found to reduce hospitalization and death risk by 90%, revealed study.